Optimizing Immunosuppression Drug Dosing Via Phenotypic Precision Medicine
Status:
Active, not recruiting
Trial end date:
2021-08-31
Target enrollment:
Participant gender:
Summary
Clinical trial applying Phenotypic Precision Medicine (PPM) to tacrolimus dosing in liver
and/or kidney transplant recipients to show improvement in maintaining drug trough levels
within the target range.
Phase:
Phase 2
Details
Lead Sponsor:
University of Florida
Collaborator:
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)